NEW YORK (GenomeWeb News) – ViraCor Laboratories and IBT Laboratories announced today that they will merge to form a new specialty diagnostic testing lab.
The merger will combine ViraCor's molecular diagnostic testing services with IBT's focus on immunology and allergy testing. Terms of the merger were not disclosed.
"This merger gives ViraCor and IBT the combined scientific know-how and national network not only to reach additional customers who could benefit from our current test menu, but also to expand our services, providing the critical diagnostic information that clinicians need to improve health outcomes for patients," ViraCor President John Martin, who will serve as president of the combined company, said in a statement.
The merged entity will employ more than 200 staffers and will serve more than 4,000 physicians, hospitals, commercial labs, and biopharmaceutical companies, the firms said.
The firm also expects to continue operating out of its two labs, which are located only 22 miles apart in the Kansas City area.